focus -WSS

focus

author：comprehensive 2025-09-09 19:28:57 - browse：54

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout LOUD podcast: The Sarepta saga, decoding biotech hype

entertainment

WSS

Lung cancer screening guidelines updated for cigarette smokers

Novo Nordisk obesity pill bests Wegovy in early trial

Just how do doctors, lawmakers, and the public define abortion?

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Inari Medical to buy amputation prevention company LimFlow

Change Healthcare payments predicted restored March 15

focus

focus

focus

As demand for Covid shots wanes, Moderna seeks its next success

Gene therapy’s promise and the high cost of hope

Apple is now the first public company to be valued at $3 trillion

Live blog: Hearing on CRISPR

State Dept. review finds Biden bears some blame for Afghanistan failures

Amylyx ALS drug fails large clinical trial

BioMarin wins approval for gene therapy to treat hemophilia A

Humans aren't the only ones with an imagination. Rats have it too

Jerome Adams on the need for new antivirals for Covid

NEJM study link tiny plastics in blood vessels to heart problems

explore

How neuroscience research could help beat back brain cancer

How to convince healthy people to buy insurance

The Readout: Amylyx, Alumis, and Lundbeck drug updates

RSV shot was 90% effective at preventing hospitalizations in kids

Life sciences investors close nearly $6 billion in new funds

Novo Nordisk obesity pill bests Wegovy in early trial

knowledge

entertainment

focus

focus